{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06138613",
            "orgStudyIdInfo": {
                "id": "VP-VLY-686-3403"
            },
            "organization": {
                "fullName": "Vanda Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness",
            "officialTitle": "Motion Delos: An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel",
            "therapeuticArea": [
                "Other"
            ],
            "study": "motion-delos-an-open-label-safety-and-efficacy-of-tradipitant-in-participants-affected-by-motion-sickness"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-03",
            "studyFirstSubmitQcDate": "2023-11-13",
            "studyFirstPostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vanda Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel",
            "detailedDescription": "This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness."
        },
        "conditionsModule": {
            "conditions": [
                "Motion Sickness"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Tradipitant Dose A",
                    "type": "EXPERIMENTAL",
                    "description": "\"See Drug\"",
                    "interventionNames": [
                        "Drug: Tradipitant"
                    ]
                },
                {
                    "label": "Tradipitant Dose B",
                    "type": "EXPERIMENTAL",
                    "description": "\"See Drug\"",
                    "interventionNames": [
                        "Drug: Tradipitant"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tradipitant",
                    "description": "Oral Capsule",
                    "armGroupLabels": [
                        "Tradipitant Dose A",
                        "Tradipitant Dose B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).",
                    "description": "Safety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.",
                    "timeFrame": "through study completion, approximately 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* History of Motion Sickness\n* Age 18-75\n\nExclusion Criteria:\n\n* Nausea-inducing disorder other than motion sickness\n* BMI \\> 40\n* History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vanda Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "2027343400",
                    "email": "clinicaltrials@vandapharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Santa Monica Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90404",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dan Norman",
                            "role": "CONTACT",
                            "phone": "310-586-0843"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009041",
                    "term": "Motion Sickness"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12002",
                    "name": "Motion Sickness",
                    "asFound": "Motion Sickness",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4872",
                    "name": "Benzoyl Peroxide",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}